Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Imsidolimab 400/200 mg	42
Overall Study	STARTED	Imsidolimab 200/100 mg	40
Overall Study	STARTED	Placebo	41
Overall Study	Safety Analysis Set	Imsidolimab 400/200 mg	41
Overall Study	Safety Analysis Set	Imsidolimab 200/100 mg	39
Overall Study	Safety Analysis Set	Placebo	41
Overall Study	COMPLETED	Imsidolimab 400/200 mg	34
Overall Study	COMPLETED	Imsidolimab 200/100 mg	34
Overall Study	COMPLETED	Placebo	37
Overall Study	NOT COMPLETED	Imsidolimab 400/200 mg	8
Overall Study	NOT COMPLETED	Imsidolimab 200/100 mg	6
Overall Study	NOT COMPLETED	Placebo	4

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04856917/flow